HK1214145A1 - 無副作用的抗癌劑 - Google Patents

無副作用的抗癌劑

Info

Publication number
HK1214145A1
HK1214145A1 HK16102091.6A HK16102091A HK1214145A1 HK 1214145 A1 HK1214145 A1 HK 1214145A1 HK 16102091 A HK16102091 A HK 16102091A HK 1214145 A1 HK1214145 A1 HK 1214145A1
Authority
HK
Hong Kong
Prior art keywords
anticancer agent
adverse reactions
agent free
free
adverse
Prior art date
Application number
HK16102091.6A
Other languages
English (en)
Inventor
賀錦．成
福島正和
江島清
加里．艾希莉
丹尼爾．
．桑蒂
Original Assignee
Delta-Fly Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta-Fly Pharma Inc filed Critical Delta-Fly Pharma Inc
Publication of HK1214145A1 publication Critical patent/HK1214145A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK16102091.6A 2013-10-04 2016-02-24 無副作用的抗癌劑 HK1214145A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013209574 2013-10-04
JP2013237219A JP5721806B2 (ja) 2013-10-04 2013-11-15 副作用のない抗癌剤
PCT/JP2014/052877 WO2015049883A1 (ja) 2013-10-04 2014-02-07 副作用のない抗癌剤

Publications (1)

Publication Number Publication Date
HK1214145A1 true HK1214145A1 (zh) 2016-07-22

Family

ID=52778484

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102091.6A HK1214145A1 (zh) 2013-10-04 2016-02-24 無副作用的抗癌劑

Country Status (7)

Country Link
JP (1) JP5721806B2 (zh)
KR (1) KR101678881B1 (zh)
CN (1) CN104981245B (zh)
HK (1) HK1214145A1 (zh)
SG (2) SG10201703378UA (zh)
TW (1) TW201513863A (zh)
WO (1) WO2015049883A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3228650T3 (pl) 2014-12-04 2022-06-27 Delta-Fly Pharma, Inc. Nowa pochodna PEG
ES2965179T3 (es) 2020-05-14 2024-04-11 Delta Fly Pharma Inc Derivado polimérico soluble en agua de venetoclax

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4694776B2 (ja) 2003-07-29 2011-06-08 株式会社ヤクルト本社 微小粒子組成物又はリポソーム製剤
EP2626083A1 (en) * 2003-09-17 2013-08-14 Nektar Therapeutics Multi-arm polymer prodrugs
KR20120044925A (ko) * 2009-04-17 2012-05-08 엔즌 파마슈티칼스, 인코포레이티드 7-에틸-10-하이드록시캄토테신의 다중-가지 고분자 복합체를 이용한 신생혈관형성 억제 방법
KR20120104158A (ko) 2009-07-22 2012-09-20 엔즌 파마슈티칼스, 인코포레이티드 7-에틸-10-히드록시캠토테신의 다분지형 중합 컨쥬게이트와 ｈｅｒ２ 수용체 길항제를 병용하여 ｈｅｒ２ 양성 암을 치료하는 방법
DK2501413T3 (da) * 2009-11-18 2019-06-11 Nektar Therapeutics Syre-saltformer af polymermedikamentkonjugater
CN102108119A (zh) * 2009-12-25 2011-06-29 天津键凯科技有限公司 多臂聚乙二醇衍生物及其与药物的结合物和凝胶
CN103025165B (zh) * 2010-05-05 2016-06-08 普罗林科斯有限责任公司 自大分子共轭物的控释

Also Published As

Publication number Publication date
SG11201506026PA (en) 2015-09-29
CN104981245A (zh) 2015-10-14
JP2015091765A (ja) 2015-05-14
WO2015049883A1 (ja) 2015-04-09
SG10201703378UA (en) 2017-05-30
CN104981245B (zh) 2017-10-03
JP5721806B2 (ja) 2015-05-20
KR101678881B1 (ko) 2016-11-23
KR20150103749A (ko) 2015-09-11
TW201513863A (zh) 2015-04-16

Similar Documents

Publication Publication Date Title
GB201421334D0 (en) Synthesis of aeizeolite
IL239203A0 (en) A semifluorocarbon compound containing a contrast agent
EP3919505C0 (en) USES OF CAS9 NUCLEIC ACID COMPLEXES
SG11201505827TA (en) Reactor
IL243323A0 (en) Anti-cancer combinations
GB2517174B (en) Assessment of structural health
HK1203811A1 (zh) 抗癌劑
EP2971029A4 (en) PREPARATION OF MALTOOLIGOSACCHARIDES
GB201320417D0 (en) Mixing reactors
SG11201507648RA (en) Liquid quick-setting agent
GB201406931D0 (en) Reactor
GB201406936D0 (en) Reactor
IL245157A0 (en) Antitumor factor
EP2837387A4 (en) ANTICANCER AGENT
GB201310202D0 (en) Agitator Assembly
EP2970642A4 (en) REFRESHING AGENTS
HK1204916A1 (zh) 淫羊藿苷元的醫藥用途
HK1214145A1 (zh) 無副作用的抗癌劑
EP2812807A4 (en) REAL PROPERTY OF SHARED DATA
GB201603522D0 (en) Pyrazolochalcones as potential anticancer agents
EP3037100A4 (en) MEANS TO PREVENT MUSCLE ATROPHY
GB201320732D0 (en) Methods of chemical synthesis
TWM476074U (en) Motherboard of vehicle
IL224699A0 (en) Protection of buildings
AP2014007847A0 (en) Diagnosis of malaria

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220205